In patients with type 2 diabetes undergoing hemodialysis, monotherapy with the DPP-IV inhibitor linagliptin was superior to monotherapy with the alpha-glucosidase inhibitor voglibose for glycemic control without severe hypoglycemia, according to study findings published in BMJ Open Diabetes Research & Care.
Katsuhito Mori, MD, PhD, of the department of metabolism, endocrinology and molecular medicine at Osaka City University Graduate School of Medicine in Osaka, Japan, evaluated 78 patients with type 2 diabetes undergoing hemodialysis randomly assigned to 12-weeks of treatment with linagliptin (Tradjenta, Boehringer Ingelheim; 5 mg; n = 40) once per day or voglibose (Basen, Takeda; 0.2 mg; n = 38) three times per day to determine the effect of each therapy. The primary outcome was change in HbA1c from baseline to the end of the 12-week treatment period.
Eighty-eight percent of all participants completed the treatment period; the discontinuation rate was greater among the voglibose group (84.2% completed) compared with the linagliptin group (92.5% completed) primarily due to adverse events.
The difference in the least squares mean change in HbA1c between baseline and week 12 was -0.4% between the linagliptin group and voglibose group (P = .022). Casual plasma glucose levels were significantly more reduced in the linagliptin group compared with the voglibose group (P = .021).
“We have shown that, compared with voglibose monotherapy, linagliptin monotherapy provides superior glycemic control without severe hypoglycemia in patients with type 2 diabetes undergoing [hemodialysis],” the researchers wrote. “We conclude that linagliptin is a promising agent for glycemic management in patients with type 2 diabetes undergoing [hemodialysis].” – by Amber Cox
Disclosure: Mori reports various financial ties with Daiichi Sankyo Co., Mitsubishi Tanbe Pharma Corporation, Nippon Boehringer Ingelheim Co. and Sanofi. Please see the full study for a list of all other authors’ relevant financial disclosures.